Adjuvant ipilimumab in stage III melanoma: New landscape, new questions

Eggermont, 2014, Cutaneous melanoma, Lancet, 383, 816, 10.1016/S0140-6736(13)60802-8 Balch, 2009, Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 27, 6199, 10.1200/JCO.2009.23.4799 Balch, 2010, Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases, J Clin Oncol, 28, 2452, 10.1200/JCO.2009.27.1627 van der Ploeg, 2010, EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria, Eur J Cancer, 46, 2414, 10.1016/j.ejca.2010.06.003 van Akkooi, 2008, Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes, Ann Surg, 248, 949, 10.1097/SLA.0b013e31818fefe0 van der Ploeg, 2011, Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria, J Clin Oncol, 29, 2206, 10.1200/JCO.2010.31.6760 van der Ploeg, 2014, The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients, Eur J Cancer, 50, 111, 10.1016/j.ejca.2013.08.023 Kirkwood, 1996, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684, J Clin Oncol, 14, 7, 10.1200/JCO.1996.14.1.7 Eggermont, 2008, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, Lancet, 372, 117, 10.1016/S0140-6736(08)61033-8 Wheatley, 2003, Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials, Cancer Treat Rev, 29, 241, 10.1016/S0305-7372(03)00074-4 Mocellin, 2010, Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis, J Natl Cancer Inst, 102, 493, 10.1093/jnci/djq009 Suciu, 2014, Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts), J Clin Oncol, 32 Garbe, 2016, Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – update 2016, Eur J Cancer, 63, 201, 10.1016/j.ejca.2016.05.005 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Wolchok, 2010, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol, 11, 155, 10.1016/S1470-2045(09)70334-1 Ascierto, 2016, Overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs. 10 mg/kg in patients with metastatic melanoma, Ann Oncol, 27 Eggermont, 2015, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 522, 10.1016/S1470-2045(15)70122-1 Eggermont, 2016, Prolonged survival with Ipilimumab as adjuvant in stage III melanoma, N Engl J Med, 10.1056/NEJMoa1611299 Coens, 2016, Phase III trial (EORTC 18071/CA184–029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results, Lancet Oncol Leiter, 2016, Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial, Lancet Oncol, 17, 757, 10.1016/S1470-2045(16)00141-8 Eggermont, 2005, Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial, Lancet, 366, 1189, 10.1016/S0140-6736(05)67482-X Eggermont, 2016, Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity, Eur J Cancer, 55, 111, 10.1016/j.ejca.2015.11.014 Eggermont, 2012, Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma, J Clin Oncol, 30, 3810, 10.1200/JCO.2011.41.3799 Eggermont, 2012, Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991, Eur J Cancer, 48, 218, 10.1016/j.ejca.2011.09.028